EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Income towards Parent Company (2010 - 2026)

EyePoint (EYPT) posted Income towards Parent Company of -$120.2 million for Q1 2026, down 77.79% sequentially from -$67.6 million in Q4 2025, and down 129.33% YoY from $409.9 million in Q1 2025.

Analysis

EyePoint (EYPT) Income towards Parent Company (2010 - 2026) Analysis & Trends

EyePoint has reported Income towards Parent Company for 17 years, with the latest figure at -$120.2 million in Q1 2026.

  • Quarterly Income towards Parent Company fell 129.33% year-over-year to -$120.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$307.0 million (down 99.33% YoY) and the FY2025 annual result came in at -$232.0 million, down 77.25% from the prior year.
  • Income towards Parent Company fell to -$120.2 million in Q1 2026 per EYPT's latest filing, from -$67.6 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$17.0 million in Q4 2023 and troughed at -$120.2 million in Q1 2026.
  • A 5-year average of -$53.2 million and a median of -$44.3 million in 2022 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company sank 643.39% in 2022, then soared 72.55% in 2023.
  • Over 5 years, Income towards Parent Company stood at -$44.3 million in 2022, then soared by 61.67% to -$17.0 million in 2023, then slumped by 143.84% to -$41.4 million in 2024, then tumbled by 63.31% to -$67.6 million in 2025, then slumped by 77.79% to -$120.2 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$120.2 million, -$67.6 million, and -$59.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -94.47 Mn
Mar 31, 2026 -87.34 Mn
Dec 31, 2025 -67.71 Mn
Sep 30, 2025 -59.73 Mn
Jun 30, 2025 -59.43 Mn
Mar 31, 2025 -48.94 Mn
Dec 31, 2024 -41.50 Mn
Sep 30, 2024 -29.36 Mn
Jun 30, 2024 -30.83 Mn
Mar 31, 2024 -33.35 Mn
Dec 31, 2023 -16.33 Mn
Sep 30, 2023 -14.40 Mn
Jun 30, 2023 -23.20 Mn
Mar 31, 2023 -22.31 Mn
Dec 31, 2022 -44.38 Mn
Sep 30, 2022 -19.01 Mn
Jun 30, 2022 -19.95 Mn
Mar 31, 2022 -19.53 Mn
Dec 31, 2021 -19.44 Mn
Sep 30, 2021 -16.70 Mn